Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab phenotyping study in chronic rhinosinusitis with nasal polyps
2018-002738-19Phase 3Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) and rhinosinusitis, sponsored by Humanitas Research Hospital. Primary endpoints: Clinical efficacy of benralizumab at week 24 and Correlation of baseline biomarkers with nasal polyp score improvement. Started Oct 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)rhinosinusitis
Beyond the preview
Go deeper on 2018-002738-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002738-19.